267 related articles for article (PubMed ID: 22134507)
1. Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase.
Kelly MP; Jungbluth AA; Wu BW; Bomalaski J; Old LJ; Ritter G
Br J Cancer; 2012 Jan; 106(2):324-32. PubMed ID: 22134507
[TBL] [Abstract][Full Text] [Related]
2. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.
Kim RH; Coates JM; Bowles TL; McNerney GP; Sutcliffe J; Jung JU; Gandour-Edwards R; Chuang FY; Bold RJ; Kung HJ
Cancer Res; 2009 Jan; 69(2):700-8. PubMed ID: 19147587
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.
Bowles TL; Kim R; Galante J; Parsons CM; Virudachalam S; Kung HJ; Bold RJ
Int J Cancer; 2008 Oct; 123(8):1950-5. PubMed ID: 18661517
[TBL] [Abstract][Full Text] [Related]
4. The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.
Thongkum A; Wu C; Li YY; Wangpaichitr M; Navasumrit P; Parnlob V; Sricharunrat T; Bhudhisawasdi V; Ruchirawat M; Savaraj N
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28587170
[TBL] [Abstract][Full Text] [Related]
5. Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
Szlosarek PW; Steele JP; Nolan L; Gilligan D; Taylor P; Spicer J; Lind M; Mitra S; Shamash J; Phillips MM; Luong P; Payne S; Hillman P; Ellis S; Szyszko T; Dancey G; Butcher L; Beck S; Avril NE; Thomson J; Johnston A; Tomsa M; Lawrence C; Schmid P; Crook T; Wu BW; Bomalaski JS; Lemoine N; Sheaff MT; Rudd RM; Fennell D; Hackshaw A
JAMA Oncol; 2017 Jan; 3(1):58-66. PubMed ID: 27584578
[TBL] [Abstract][Full Text] [Related]
6. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.
Feun LG; Marini A; Walker G; Elgart G; Moffat F; Rodgers SE; Wu CJ; You M; Wangpaichitr M; Kuo MT; Sisson W; Jungbluth AA; Bomalaski J; Savaraj N
Br J Cancer; 2012 Apr; 106(9):1481-5. PubMed ID: 22472884
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20).
Burrows N; Cane G; Robson M; Gaude E; Howat WJ; Szlosarek PW; Pedley RB; Frezza C; Ashcroft M; Maxwell PH
Sci Rep; 2016 Mar; 6():22950. PubMed ID: 26972697
[TBL] [Abstract][Full Text] [Related]
8. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.
Delage B; Luong P; Maharaj L; O'Riain C; Syed N; Crook T; Hatzimichael E; Papoudou-Bai A; Mitchell TJ; Whittaker SJ; Cerio R; Gribben J; Lemoine N; Bomalaski J; Li CF; Joel S; Fitzgibbon J; Chen LT; Szlosarek PW
Cell Death Dis; 2012 Jul; 3(7):e342. PubMed ID: 22764101
[TBL] [Abstract][Full Text] [Related]
9. Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy.
Walts AE; Bomalaski JS; Ines D; Orsulic S
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1363-9. PubMed ID: 25548129
[TBL] [Abstract][Full Text] [Related]
10. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
Kuo MT; Savaraj N; Feun LG
Oncotarget; 2010 Aug; 1(4):246-51. PubMed ID: 21152246
[TBL] [Abstract][Full Text] [Related]
11. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW
Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM.
Przystal JM; Hajji N; Khozoie C; Renziehausen A; Zeng Q; Abaitua F; Hajitou A; Suwan K; Want E; Bomalaski J; Szlosarek P; O'Neill K; Crook T; Syed N
Cell Death Dis; 2018 Dec; 9(12):1192. PubMed ID: 30546006
[TBL] [Abstract][Full Text] [Related]
13. Decreased argininosuccinate synthetase expression in Thai patients with cholangiocarcinoma and the effects of ADI-PEG20 treatment in CCA cell lines.
Roeksomtawin S; Navasumrit P; Waraprasit S; Parnlob V; Sricharunrat T; Bhudhisawasdi V; Savaraj N; Ruchirawat M
Oncol Lett; 2018 Aug; 16(2):1529-1538. PubMed ID: 30008833
[TBL] [Abstract][Full Text] [Related]
14. Arginine deprivation as a targeted therapy for cancer.
Feun L; You M; Wu CJ; Kuo MT; Wangpaichitr M; Spector S; Savaraj N
Curr Pharm Des; 2008; 14(11):1049-57. PubMed ID: 18473854
[TBL] [Abstract][Full Text] [Related]
15. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
[TBL] [Abstract][Full Text] [Related]
16. Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.
Savaraj N; Wu C; Li YY; Wangpaichitr M; You M; Bomalaski J; He W; Kuo MT; Feun LG
Oncotarget; 2015 Mar; 6(8):6295-309. PubMed ID: 25749046
[TBL] [Abstract][Full Text] [Related]
17. Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation.
Singh PK; Deorukhkar AA; Venkatesulu BP; Li X; Tailor R; Bomalaski JS; Krishnan S
Mol Cancer Ther; 2019 Dec; 18(12):2381-2393. PubMed ID: 31395686
[TBL] [Abstract][Full Text] [Related]
18. Amino Acid Uptake Measured by [
Prudner BC; Sun F; Kremer JC; Xu J; Huang C; Sai KKS; Morgan Z; Leeds H; McConathy J; Van Tine BA
Theranostics; 2018; 8(8):2107-2116. PubMed ID: 29721066
[No Abstract] [Full Text] [Related]
19. Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
Manca A; Sini MC; Izzo F; Ascierto PA; Tatangelo F; Botti G; Gentilcore G; Capone M; Mozzillo N; Rozzo C; Cossu A; Tanda F; Palmieri G
Oncol Rep; 2011 Jun; 25(6):1495-502. PubMed ID: 21424129
[TBL] [Abstract][Full Text] [Related]
20. Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.
Fiedler T; Strauss M; Hering S; Redanz U; William D; Rosche Y; Classen CF; Kreikemeyer B; Linnebacher M; Maletzki C
Cancer Biol Ther; 2015; 16(7):1047-55. PubMed ID: 25774632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
